Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration

To evaluate the efficacy and safety of ranibizumab 0.5 mg treat-and-extend (T&E) versus monthly regimens in patients with neovascular age-related macular degeneration (nAMD) from the TReat and extEND (TREND) study.

http://www.aaojournal.org/article/S0161-6420(17)31025-4/fulltext?rss=yes

Source: Ophthalmology - September 8, 2017 Category: Opthalmology Authors: Rufino Silva, Andr ás Berta, Michael Larsen, Wayne Macfadden, Chrystel Feller, Jordi Monés, TREND Study Group Source Type: research

More News: Age-Related Macular Degeneration (AMD) | Lucentis | Opthalmology | Ranibizumab Injection | Study